Lucjan Wyrwicz

14PUBLICATIONS
117CO-AUTHORS
Molecular targetsOncology and carcinogenesis not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 13, 2026
A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus.

|Apr 11, 2026
Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction cancer: KEYNOTE-859 Q-TWiST analysis.

Lucjan Wyrwicz, Vasiliki Kalampoki, Adriana Valderrama

|Nov 18, 2025
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up.

Marcia Cruz-Correa, Do-Youn Oh, Ken Kato

|Aug 19, 2025
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study.

Kohei Shitara, Sun Young Rha, Lucjan Wyrwicz

|May 31, 2025
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.

Kohei Shitara, Sylvie Lorenzen, Jin Li

|May 31, 2025
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.

Hani M Babiker, Vincent Picozzi, Sreenivasa R Chandana

Pageof 3

Frequent Collaborators

5 joint publications

Kohei Shitara

4 joint publications

Keun-Wook Lee

4 joint publications

Sun Young Rha

4 joint publications

Roberto Pazo-Cid